CCLM:儿童CRP,LEP和LEPR基因多态性与高敏C反应蛋白水平的关系

2017-10-31 MedSci MedSci原创

近日,国际杂志《Clinical Chemistry and Laboratory Medicine》在线发表了一篇关于儿童CRP,LEP和LEPR基因多态性与高敏C反应蛋白水平的关系的研究。调查了健康西班牙儿童的两个独立队列中C反应蛋白(CRP),瘦素(LEP)和瘦素受体(LEPR)基因中单核苷酸多态性(SNPs)与高敏感性CRP(hs-CRP)水平的关系。

近日,国际杂志《Clinical Chemistry and Laboratory Medicine》在线发表了一篇关于儿童CRPLEPLEPR基因多态性与高敏C反应蛋白水平的关系的研究。调查了健康西班牙儿童的两个独立队列中C反应蛋白(CRP),瘦素(LEP)和瘦素受体(LEPR)基因中单核苷酸多态性(SNPs)与高敏感性CRPhs-CRP)水平的关系。

研究人员使用高灵敏度C反应蛋白ELISA试剂盒测量6466-8岁,70712-16岁儿童的hs-CRP水平。通过TaqMan测定®等位基因鉴别测定CRP基因(rs1205rs1130864rs2794521rs1800947)的4SNP位点,LEP基因(rs7799039)的一个SNPLEPRrs1137100rs1137101)基因的两个SNP

研究结果表明,在两个队列中的四个CRP SNPhs-CRP水平相关联显着(p <0.05)。此外,两个常见的CRP单倍型(使用SNPs按顺序:rs1205rs1130864rs1800947rs2794521ACGAGCGG相互关联,两者均具有显著的较低CRP水平(p <0.05)。LEPR SNPs rs1137100K109R)和rs1137101Q223R)和LEP SNP rs7799039G2548A)在两组中均与hs-CRP水平(p <0.05)有关。

结果表明,健康西班牙儿童的hs-CRP水平除了与CRP基因中的常见多态性相关,还与LEPLEPR基因中的多态性相关,这表明其他的CRP基因位点可能具有决定CRP水平的作用。

原始出处:

Navarro, Pilar. et.al. Relationship between polymorphisms in the CRP, LEP and LEPR genes and high sensitivity C-reactive protein levels in Spanish children.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1269595, encodeId=332c126959542, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Thu Nov 02 01:46:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297824, encodeId=8a5e129e824bf, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Thu Nov 02 01:46:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614813, encodeId=9a731614813b3, content=<a href='/topic/show?id=49d810240513' target=_blank style='color:#2F92EE;'>#高敏C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102405, encryptionId=49d810240513, topicName=高敏C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61fa19545213, createdName=1249884fm93暂无昵称, createdTime=Thu Nov 02 01:46:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629236, encodeId=2e4e1629236b0, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Thu Nov 02 01:46:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257494, encodeId=697f25e4945b, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Oct 31 11:56:06 CST 2017, time=2017-10-31, status=1, ipAttribution=)]
    2017-11-02 rebeccajiejie
  2. [GetPortalCommentsPageByObjectIdResponse(id=1269595, encodeId=332c126959542, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Thu Nov 02 01:46:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297824, encodeId=8a5e129e824bf, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Thu Nov 02 01:46:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614813, encodeId=9a731614813b3, content=<a href='/topic/show?id=49d810240513' target=_blank style='color:#2F92EE;'>#高敏C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102405, encryptionId=49d810240513, topicName=高敏C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61fa19545213, createdName=1249884fm93暂无昵称, createdTime=Thu Nov 02 01:46:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629236, encodeId=2e4e1629236b0, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Thu Nov 02 01:46:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257494, encodeId=697f25e4945b, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Oct 31 11:56:06 CST 2017, time=2017-10-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1269595, encodeId=332c126959542, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Thu Nov 02 01:46:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297824, encodeId=8a5e129e824bf, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Thu Nov 02 01:46:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614813, encodeId=9a731614813b3, content=<a href='/topic/show?id=49d810240513' target=_blank style='color:#2F92EE;'>#高敏C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102405, encryptionId=49d810240513, topicName=高敏C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61fa19545213, createdName=1249884fm93暂无昵称, createdTime=Thu Nov 02 01:46:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629236, encodeId=2e4e1629236b0, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Thu Nov 02 01:46:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257494, encodeId=697f25e4945b, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Oct 31 11:56:06 CST 2017, time=2017-10-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1269595, encodeId=332c126959542, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Thu Nov 02 01:46:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297824, encodeId=8a5e129e824bf, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Thu Nov 02 01:46:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614813, encodeId=9a731614813b3, content=<a href='/topic/show?id=49d810240513' target=_blank style='color:#2F92EE;'>#高敏C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102405, encryptionId=49d810240513, topicName=高敏C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61fa19545213, createdName=1249884fm93暂无昵称, createdTime=Thu Nov 02 01:46:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629236, encodeId=2e4e1629236b0, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Thu Nov 02 01:46:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257494, encodeId=697f25e4945b, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Oct 31 11:56:06 CST 2017, time=2017-10-31, status=1, ipAttribution=)]
    2017-11-02 xzw120
  5. [GetPortalCommentsPageByObjectIdResponse(id=1269595, encodeId=332c126959542, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Thu Nov 02 01:46:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297824, encodeId=8a5e129e824bf, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Thu Nov 02 01:46:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614813, encodeId=9a731614813b3, content=<a href='/topic/show?id=49d810240513' target=_blank style='color:#2F92EE;'>#高敏C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102405, encryptionId=49d810240513, topicName=高敏C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61fa19545213, createdName=1249884fm93暂无昵称, createdTime=Thu Nov 02 01:46:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629236, encodeId=2e4e1629236b0, content=<a href='/topic/show?id=0c1c4325170' target=_blank style='color:#2F92EE;'>#多态性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43251, encryptionId=0c1c4325170, topicName=多态性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d83c21331263, createdName=xzw120, createdTime=Thu Nov 02 01:46:00 CST 2017, time=2017-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257494, encodeId=697f25e4945b, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Oct 31 11:56:06 CST 2017, time=2017-10-31, status=1, ipAttribution=)]
    2017-10-31 1ddf0692m34(暂无匿称)

    学习了.涨知识

    0

相关资讯

Int J Impot Res:多巴胺基因多态性与早泄病人对帕罗西汀和依他普伦响应关系的研究

最近,有研究人员评估了终生早泄(LPE)病人中,多巴胺(DA)转运基因的多态性和它在对帕罗西汀和依他普伦响应中的角色。研究招募了80名连续病人和对照。其中,有60名遭受LPE。研究人员将他们分成两个相等的小组。其中一个小组接受20mg每天的帕罗西汀,并持续3个月,另一个小组接受20mg每天的依他普伦,同样持续3个月。研究人员还邀请他们的妻子利用码表来对阴道内射精等待时间进行了测量。另外,研究人员还

Chest:p53信号通路与肺气肿的相关性

p53信号通路可能在吸烟者的肺气肿发病机制中扮演重要角色。目前已知,p53在密码子72的多态性可以影响凋亡效应蛋白,并且小鼠双微小体2同源物(MDM2)SNP309的多态性可以增加MDM2的表达。近期,一项发表在杂志Plos One上的研究旨在评估吸烟者中的p53和MDM2的基因多态性,并评估这些基因中的SNPs在肺气肿发病机制中的作用。此项研究共纳入了365例吸烟患者,并确定了p53和MDM2基

Circulation:急性缺血性卒中/TIA基因多态性和氯吡格雷疗效的荟萃分析

相比于缺血性卒中或TIA接受氯吡格雷治疗的CYP2C19功能缺失等位基因非携带者,CYP2C19功能缺失等位基因携带者有更高的卒中和复合心血管事件发生风险。

J Rheumatol:幼年特发性关节炎中甲氨蝶呤基因多态性与治疗效果的关系

不同MTX代谢途径的SNP影响MTX治疗。与功效相比,遗传变异性是毒性更好的标志物。

J Rheumatol:弥漫性皮肤系统性硬化症中MIF启动子多态性与肺动脉高压易感性相关

这项研究证实了MIF rs755622 * C等位基因与SSc的关联,并描述了该变体与dcSSc患者发生PAH易感性的表型特异性关联。

Sci Rep:lncRNA-p53调控网络的基因多态性或可改善鼻咽癌患者的预后

转录因子p53与癌症的相关性是不容争辩的,很多lncRNAs作为调控者或者被调控者参与了p53调控网络,引发转录反应,导致细胞周期阻滞和凋亡。尽管鼻咽癌的治疗反应有所改善,但是患者之间的异质性仍然会影响患者对不良反应的易感性和治疗效果。本研究中,研究人员共纳入了505例鼻咽癌患者,分析了lncrna-p53调控网络中五个基因的八个潜在的功能SNPs。通过多因素logistic回归分析,研究了遗传变